megestrol has been researched along with fadrozole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chinchilli, VM; Demers, L; Grossberg, H; Harvey, H; Konrad, K; Leitzel, K; Lipton, A; Teramoto, Y; Volas, G | 1 |
| Bonomi, P; Buzdar, AU; Cooper, J; Favis, G; Keller, AM; Mulagha, M; Smith, R; Vogel, C | 1 |
| Demers, L; Grossberg, H; Leitzel, K; Lipton, A; Teramoto, Y; Volas, GH | 1 |
3 trial(s) available for megestrol and fadrozole
| Article | Year |
|---|---|
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens; Breast Neoplasms; Chi-Square Distribution; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Gene Amplification; Humans; Megestrol; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Regression Analysis; Survival Analysis; Tamoxifen; Treatment Outcome | 1995 |
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Double-Blind Method; Fadrozole; Female; Humans; Megestrol; Menopause; Middle Aged; Prognosis; Prospective Studies; Survival Analysis | 1996 |
Serial serum c-erbB-2 levels in patients with breast carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Fadrozole; Female; Humans; Megestrol; Megestrol Acetate; Placebos; Prognosis; Receptor, ErbB-2; Remission Induction; Treatment Outcome | 1996 |